COMPARATIVE EVALUATION OF EFFICACY AND SAFETY OF TOPICAL METHOTREXATE WITH TRETINOIN VERSUS BETAMETHASONE WITH TRETINOIN IN PATIENTS OF ALOPECIA AREATA: A PROSPECTIVE RANDOMIZED DOUBLE-BLIND STUDY
DOI:
https://doi.org/10.22159/ajpcr.2024v17i10.52008Keywords:
Alopecia areata, Methotrexate,, Betamethasone, Tretinoin, Topical.Abstract
Objectives: Alopecia areata (AA) is a reiterative and non-scarring type of hair loss that can affect any hairy area of the body, particularly the scalp. The present study is aimed at comparing the safety and efficacy of methotrexate with tretinoin versus betamethasone with tretinoin in patients of AA.
Methods: A prospective and comparative study was carried out in 80 cases of AA in Gajra Raja Medical College, Gwalior (M.P.) from December 2022 to November 2023. Subjects were randomly allocated to two groups, namely, MXT and BMT, 40 patients in each group. In group MXT, patients were asked to apply methotrexate 1% gel in the morning and tretinoin 0.025% cream in the evening, and in group BMT patients were asked to apply betamethasone 0.05% cream once daily in the morning and tretinoin 0.025% cream in the evening for 6 months. Mean severity of alopecia tool (SALT) score, mean regrowth scale (RGS) score, and adverse drug reactions due to treatments were recorded at 0, 3, and 6 months.
Results: Mean SALT score decreased from 4.40 to 0.57 in MXT and from 3.34 to 0.63 in BMT group after 6 months and is significant (p<0.05) from baseline values. MXT showed a better response, than BMT group but was not significant (p>0.05). RGS Grade 3 was observed in 13% of patients and RGS Grade 4 was observed in 87% of patients in MXT group patients. RGS Grade 3 was observed in 19% of patients and RGS Grade 4 was observed in 81% of patients in BMT group. On intergroup comparison, a greater number of patients treated with methotrexate and tretinoin showed RGS Grade 4 as compared to patients treated with betamethasone and tretinoin treated group but was not significant (p>0.05). Twenty-five patients in the MXT group and 17 patients in BMT group showed mild adverse drug reactions at the end of 1 month that included burning, itching, redness, stinging, folliculitis, and scaling and all were resolved with minor treatment.
Conclusion: Topical methotrexate is more efficacious and equally safe as betamethasone, making it the first line of drug for the management of AA.
Downloads
References
Strazzulla LC, Wang EH, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018 Jan;78(1):1-12. doi: 10.1016/j.jaad.2017.04.1141., PMid: 29241771
Okhovat JP, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis. J Am Acad Dermatol. 2023 May;88(5):1040-50. doi: 10.1016/j.jaad.2019.05.086, PMid: 31163237
Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: A review of disease pathogenesis. Br J Dermatol. 2018 Nov;179(5):1033-48. doi: 10.1111/bjd.16808, PMid: 29791718
Tosti A, Bellavista S, Iorizzo M. Alopecia areata: A long term follow-up study of 191 patients. J Am Acad Dermatol. 2006 Sep;55(3):438-41. doi: 10.1016/j.jaad.2006.05.008, PMid: 16908349
Sibbald C. Alopecia areata: An updated review for 2023. J Cutan Med Surg. 2023 May-Jun;27(3):241-59. doi: 10.1177/12034754231168839, PMid: 37340563
Malhotra K, Madke B. An updated review on current treatment of alopecia areata and newer therapeutic options. Int J Trichology. 2023 Jan-Feb;15(1):3-12. doi: 10.4103/ijt.ijt_28_21, PMid: 37305188
Kumaresan M. Intralesional steroids for alopecia areata. Int J Trichology. 2010 Jan;2(1):63-5. doi: 10.4103/0974-7753.66920, PMid: 21188031
Gupta P, Verma KK, Khandpur S, Bhari N. Weekly azathioprine pulse versus betamethasone oral mini-pulse in the treatment of moderate-to-severe alopecia areata. Indian J Dermatol. 2019 Jul-Aug;64(4):292-8. doi: 10.4103/ijd.IJD_481_16, PMid: 31516138
Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: A review. Drug Des Devel Ther. 2019 Aug 9;13:2777-86. doi: 10.2147/DDDT.S214907. Erratum in: Drug Des Devel Ther. 2020 Feb 10;14:575. doi: 10.2147/DDDT.S247601, PMid: 31496654
Das S, Ghorami RC, Chatterjee T, Banerjee G. Comparative assessment of topical steroids, topical tretenoin (0.05%) and dithranol paste in alopecia areata. Indian J Dermatol. 2010 Apr-Jun;55(2):148-9. doi: 10.4103/0019-5154.62747, PMid: 20606883
Royer M, Bodemer C, Vabres P, Pajot C, Barbarot S, Paul C, et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol. 2011 Aug;165(2):407-10. doi: 10.1111/j.1365- 2133.2011.10383.x, PMID: 21517797
Hammerschmidt M, Mulinari Brenner F. Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol. 2014 Sep-Oct;89(5):729-34. doi: 10.1590/abd1806-4841.20142869, PMid: 25184911
Ahmed G, Khare S, Ganguly S, Chhabra N, Prabha N. Topical methotrexate 1% gel for the treatment of localized alopecia areata. Int J Dermatol. 2020 Aug;59(8):e292-3. doi: 10.1111/ijd.14898, PMid: 32346854
Kagami S, Kishi Y, Hino H. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata. J Cosmet Dermatol. 2020 Sep;19(9):2411-4. doi: 10.1111/jocd.13588, PMid: 32621407
Ruchiatan K, Avriyanti E, Hindritiani R, Puspitosari D, Suwarsa O, Gunawan H. Successful therapy of alopecia universalis using a combination of systemic methotrexate and corticosteroids and topical 5% minoxidil. Clin Cosmet Investig Dermatol. 2022 Jan 25;15:127-32. doi: 10.2147/CCID.S349683, PMid: 35115800
Hussain AA. A comparative study of the outcomes of potent topical steroids versus topical tretinoin in patchy alopecia areata of scalp. Int J Res Dermatol. 2020;6(1):111-4. doi: 10.18203/issn.2455-4529. intjresdermatol20195684
Zhou C, Li X, Wang C, Zhang J. Alopecia areata: An update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021 Dec;61(3):403-23. doi: 10.1007/s12016-021-08883-0, PMid: 34403083
Kutlubay Z, Sevim A, Aydın Ö, Vehid S, Serdaroğlu S. Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata. Turk J Med Sci. 2020 Dec 17;50(8):1817-24. doi: 10.3906/sag- 1807-230, PMid: 31655499
Sardesai VR, Prasad S, Agarwal TD. A study to evaluate the efficacy of various topical treatment modalities for alopecia areata. Int J Trichology. 2012 Oct;4(4):265-70. doi: 10.4103/0974-7753.111223, PMid: 23766611
Anuset D, Perceau G, Bernard P, Reguiai Z. Efficacy and safety of methotrexate combined with low-to moderate-dose corticosteroids for severe alopecia areata. Dermatology. 2016;232(2):242-8. doi: 10.1159/000441250, PMid: 26735937
Alsantali A. Alopecia areata: A new treatment plan. Clin Cosmet Investig Dermatol. 2011;4:107-15. doi: 10.2147/CCID.S22767, PMid: 21833161
Bazzano GS, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol. 1986 Oct;15(4 Pt 2):880-3, 890-3. doi: 10.1016/s0190-9622(86)80024-x, PMid: 3771854
Aslam S, Awan AZ, Iqbal MM, Saeed S, Saeed M, Liaqat Z, et al. Comparison of efficacy of topical betamethasone dipropionate and topical minoxidil in patients with alopecia areata. Cureus. 2024 Mar 16;16(3):e56282. doi: 10.7759/cureus.56282, PMid: 38623137
Published
How to Cite
Issue
Section
Copyright (c) 2024 Saroj Kothari, Vaibhav Vivek Kalgaonkar, Sanjay Kumar R, Anubhav Garg, Rajkumar Arya
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
